

## REMARKS

Applicants submit the present claims for consideration by the Examiner. Claims 1, 2, 7, 8 and 13 have been amended and claims 3-6 and 20 have been cancelled. Claims 21-28 have been added.

Support for the amendments can be found at page 7, lines 8-22, and in U.S. Patent No. 5,478,852 (the '852 patent) which is incorporated into the specification by reference. Support in the '852 patent for the compounds identified in the claims exists as follows: troglitazone (col. 14, lines 60-62), ciglitazone (col. 15, lines 8-9), pioglitazone (col. 15, lines 14-15), 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione (col. 15, lines 28-29), and englitazone (col. 15, lines 16-17). The pharmaceutically acceptable salts of the claimed compounds are identified at column 15, line 38 - column 16, line 28 of the '852 patent. The '852 patent is cited on page 7, lines 12, 16 and 19, and incorporated by reference at page 11, lines 24-25, of the present application. Accordingly, no new matter has been added.


If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

It is submitted that the claims are in condition for allowance and such allowance is respectfully solicited.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: September 23, 2003

By:   
Deborah J. Ackey  
Reg. No. 48,916

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com